Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||IMO-2125 + Ipilimumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|IMO-2125||Tilsotolimod||TLR Antibody 8||Tilsotolimod (IMO-2125) is an immunomodulatory oligonucleotide (IMO) that targets toll-like receptor 9 (TLR9), resulting in activation of anti-tumor immunity (PMID: 23207140).|
|Ipilimumab||Yervoy||BMS-734016||CTLA4 Antibody 16 Immune Checkpoint Inhibitor 94||Yervoy (ipilimumab) is an antibody that binds to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), causing increased T-cell activation (PMID: 28891423). Yervoy (ipilimumab) is FDA approved for use in patients with metastatic melanoma, including patients 12 years or older, and in combination with Opdivo (nivolumab) for intermediate or poor-risk renal cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (including patients 12 years or older), hepatocellular carcinoma previously treated with Nexavar (sorafenib), in combination with Opdivo (nivolumab) as first-line therapy in patients with PD-L1-positive (>=1%) metastatic non-small cell lung cancer without EGFR or ALK alterations, and in combination with Opdivo (nivolumab) and platinum-based chemotherapy as first-line therapy in patients with metastatic or recurrent non-small cell lung cancer without EGFR or ALK alterations (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02644967||Phase Ib/II||IMO-2125 + Ipilimumab IMO-2125 + Pembrolizumab||A Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma||Completed|
|NCT03445533||Phase III||Ipilimumab IMO-2125 + Ipilimumab||A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE 301)||Active, not recruiting|